Accentia Biopharmaceuticals Inc (1310094) SEC Filing 10-Q Quarterly report for the period ending Monday, December 31, 2012

Accentia Biopharmaceuticals Inc

CIK: 1310094

View differences made from one quarter to another to evaluate Accentia Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Accentia Biopharmaceuticals Inc.


Assess how Accentia Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Accentia Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1310094
Form Type: 10-Q Quarterly Report
Accession Number: 0001214659-13-000877
Submitted to the SEC: Thu Feb 14 2013 5:22:59 PM EST
Accepted by the SEC: Thu Feb 14 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink: